Hemogenyx Pharmaceuticals Plc announced the appointment of Sir Marc Feldmann, AC, FRS, as Executive Chairman effective as of April 9, 2018. He has a unique blend of scientific, medical and commercial experience and expertise. Sir Marc was previously Chairman of the company's Scientific Advisory Board and has a remarkably broad experience of discovering new medicines, having worked through all stages from developing new concepts of how diseases emerge, through testing ideas and early clinical development, leading clinical trials, approval, registration and commercial reality. Robin Campbell, Chairman, will become a Non-Executive Director and Adrian Beeston, Non-Executive Director, will step down from the Board, both with immediate effect.